Beyond Air, Inc. (NASDAQ: XAIR) announced on July 30, 2026 that it has entered into a securities purchase agreement expected to generate up to $30.1 million in aggregate gross proceeds — before placement agent fees and expenses — assuming full cash exercise of all accompanying warrants.

The deal prices 167,011 shares of common stock plus warrants at $5.66 per combined share to institutional investors, and at $5.76 per combined share to directors and officers. The offering also includes pre-funded warrants to purchase up to 1,638,835 shares at $5.6599 per share. Closing is expected on or about July 31, 2026, per the company's July 30 news release.

Beyond Air intends to use net proceeds for working capital and general corporate purposes.

The Garden City, New York-based medical device and biopharmaceutical company develops nitric oxide-based therapies for respiratory disease. Its LungFit PH system holds approval for sale in the United States, the European Union, and numerous other countries. The company operates through three segments: Beyond Air, Beyond Cancer, and NeuroNos.

In Q3 fiscal 2026, Beyond Air exceeded $2.0 million in quarterly revenue — a 21% sequential increase and a 105% increase over the same quarter the prior year, per the company's disclosures. Over the trailing twelve months, the company reported $7.68 million in revenue alongside losses of $33.25 million. As of the most recent reporting date, the balance sheet carried $11.64 million in cash and $23.38 million in debt, per the company's disclosures.

Beyond Air is also targeting a near-term regulatory milestone: the company expects FDA clearance of its second-generation LungFit PH system before the end of calendar 2026, per the July 30 news release.

Leadership at the company changed earlier this year. Steve Lisi resigned as CEO effective March 27, 2026, with Robert Goodman taking over as the new chief executive.

As of the most recent reporting date, Beyond Air had 720,531 shares outstanding. The stock has traded in a 52-week range of $0.335 to $5.842, per Robinhood data as of July 25, 2026, which also showed a price of $5.16 and a one-year price change of -91.450%.

What comes next is concrete: a July 31 closing, net proceeds directed to working capital and general corporate purposes, and a clock running on the second-generation LungFit PH FDA clearance decision before December 31, 2026.